A Health Economic Evaluation of Using N-Terminal Pro Brain Natriuretic Peptide (NT-pro BNP) for Management of Acute Heart Failure in a Tertiary Referral Hospital in Jakarta, Indonesia
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Heart Failure
- Sponsor
- Heart Failure Biomarker Group
- Enrollment
- 56
- Locations
- 1
- Primary Endpoint
- Mortality rate
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
Cardiac biomarkers have dramatically impacted the way HF patients are evaluated and managed. In fact, the role of biomarkers has developed to better differentiate HF against other diseases and, to timely initiate and influence more accurate diagnosis (rule out) and treatments, to predict the onset of future HF, to risk-stratify affected patients, and to serve as a tool to guide intensity of therapy. NT-proBNP has become validated biomarkers with highest guideline recommendation (class I) and independent predictors for re-hospitalization and mortality in HF patients. However, many Indonesian cardiologists do not use of those biomarkers, mostly due to limited available cardiac biomarkers for the cost effective heart failure management. We evaluate 2 alternative treatments which one that more cost-effective between biomarker's guided therapy and without biomarker.
Detailed Description
With growing demands on limited health care budgets, optimal resource allocation in HF patients is essential. Although NT pro BNP is proposed to be effective for the evaluation and management patients with heart failure, no data exist about cost-effectiveness analysis that are based on practice patterns endorsed by universal coverage systems in Indonesia (Jaminan Kesehatan Nasional). Because NT-proBNP therapy guidance in HF is believed to create additional costs, it is not yet broadly applicable. Its why we need to elaborate this issue.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients aged 18-75 years
- •The primary diagnosis at the Emergency Department (ED) is acute decompensated heart failure (ADHF)
- •Using the national health insurance
- •Willing to be followed for 3 months
- •Willing to sign informed consent.
Exclusion Criteria
- •Severe life-threatening comorbidities with a life expectancy of \<2 years
- •Acute heart failure other than ADHF such as acute pulmonary edema, acute heart failure in the setting of acute coronary syndrome, cardiogenic shock, right heart failure, and hypertensive heart failure
- •ADHF accompanied by sepsis, liver disease, lung disease with severe radiological findings, mechanical complications of acute myocardial infarction, aortic dissection, congenital heart disease, idiopathic pulmonary hypertension, lung emboli, severe respiratory failure, and severe burns
- •Patients admitted to ICVCU (Intensive Cardiovascular Care Unit)
- •Patients did not take medication regularly and controls routinely.
Outcomes
Primary Outcomes
Mortality rate
Time Frame: 3 months after discharge
Percentage of patients who are death post discharge (%)
Rehospitalization rate
Time Frame: 3 months after discharge
Percentage of patients who readmit and are hospitalized because of heart failure (%)
Emergency department visit
Time Frame: 3 months after discharge
Percentage of patients who readmit and are not hospitalized because of heart failure (%)
Secondary Outcomes
- Cost(Admission to hospital until 3 months after discharge)